MichaelToddDellingerDO

PubMed

• 57 citations
  Impaired meningeal lymphatic vessel development worsens stroke outcome.
  Pavel Yanev, Katherine Poinsatte, Devon Hominick, Noor Khurana, Kielen R Zuurbier, Marcus Berndt, Erik J. Plautz, Michael T. Dellinger, Ann M. Stowe> ;Journal of Cerebral Blood Flow and Metabolism. 2020 Feb 1
• 14 citations
  Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical ...
  Yuqing Zhang, Amanda Kirane, Huocong Huang, Francis Burrows, Michael T. Dellinger, Rolf A. Brekken> ;Molecular Cancer Research. 2019 Feb 1
• 27 citations
  Mir-126 is a conserved modulator of lymphatic development.
  Zacharias Kontarakis, Andrea Rossi, Sophie Ramas, Michael T. Dellinger, Didier Y.R. Stainier> ;Developmental Biology. 2018 May 15
• 12 citations
  Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.
  Erin Regan, Robert C. Sibley, Bercin Kutluk Cenik, Asitha Silva, Luc Girard, John D. Minna, Michael T. Dellinger> ;Plos One. 2016 Mar 7
• 102 citations
  Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
  Amanda Kirane, Kathleen Ludwig, Gry S. Haaland, Tone Sandal, Renate Ranaweera, Jason E. Toombs, Miao Wang, Sean P. Dineen, David Micklem, Michael T. Dellinger, James B...> ;Cancer Research. 2015 Sep 15
• 71 citations
  Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma
  Kristina Y. Aguilera, Lee B. Rivera, Hoon Hur, Juliet G. Carbon, Jason E. Toombs, Courtney D. Goldstein, Michael T. Dellinger, Diego H. Castrillon, Rolf A. Brekken> ;Cancer Research. 2014 Feb 15
• 52 citations
  Vascular Endothelial Growth Factor Receptor-2 Promotes the Development of the Lymphatic Vasculature
  Michael T. Dellinger, Stryder M. Meadows, Katherine W. Wynne, Ondine Cleaver, Rolf A. Brekken> ;Plos One. 2013 Sep 2
• 88 citations
  RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
  Georgia Konstantinidou, Giorgio Ramadori, Francesca Torti, Kim Kangasniemi, Rachel E. Ramirez, Yiran Cai, Carmen Behrens, Michael T. Dellinger, Rolf A. Brekken, Ignaci...> ;Cancer Discovery. 2013 Jan 28
• 29 citations
  Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model
  Xinyu Li, Qinbo Zhou, Jakub Hanus, Chastain Anderson, Hongmei Zhang, Michael T. Dellinger, Rolf A. Brekken, Shusheng Wang> ;Molecular Pharmaceutics. 2013 Jan 7
• 30 citations
  Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
  David E. Gerber, Puja Gupta, Michael T. Dellinger, Jason E. Toombs, Michael Peyton, Inga J Duignan, Jennifer Malaby, Timothy Bailey, Colleen A. Burns, Rolf A. Brekken,...> ;Molecular Cancer Therapeutics. 2012 Nov 1
• 4 citations
  Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia
  Marlys H. Witte, Michael T. Dellinger, Cristobal M. Papendieck, Francesco Boccardo> ;Clinical & Experimental Metastasis. 2012 Jul 15
• 67 citations
  Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.
  Michael T. Dellinger, Rolf A. Brekken> ;Plos One. 2011 Dec 12
• 137 citations
  Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax
  John D. Kanady, Michael T. Dellinger, Stephanie J. Munger, Marlys H. Witte, Alexander M. Simon> ;Developmental Biology. 2011 Jun 15
• The effects of targeting stromal and tumor cell platelet-derived growth factor receptor (PDGFR) in non-small cell lung cancer (NSCLC).
  Gerber DE, Gupta P, Dellinger MT, Toombs J, Valencia I, Peyton M, Loizos N, Brekken RA> ;J. Clin. Oncol.. 2011-05-20
• 27 citations
  Lymphangiogenesis and Hemangiogenesis: Potential Targets for Therapy
  Marlys H. Witte, Michael T. Dellinger, Donald M. McDonald, S. David Nathanson, Francesco Boccardo, Corradino Campisi, Jonathan P. Sleeman, Jeffrey E. Gershenwald> ;Journal of Surgical Oncology. 2011 May 1
• 10 citations
  Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2.
  Marlys H. Witte, Robert P. Erickson, M. Khalil, Michael T. Dellinger, Michael Bernas, T. Grogan, H. Nitta, J. Feng, D. Duggan, Charles L. Witte> ;Lymphology. 2009 Dec 1
• 133 citations
  Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
  Christina L. Roland, Sean P. Dineen, Kristi D. Lynn, Laura A. Sullivan, Michael T. Dellinger, Leila Sadegh, James P. Sullivan, David S. Shames, Rolf A. Brekken> ;Molecular Cancer Therapeutics. 2009 Jul 1
• 17 citations
  Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review.
  Michael T. Dellinger, K. Thome, Michael Bernas, Robert P. Erickson, Marlys H. Witte> ;Lymphology. 2008 Aug 20
• 139 citations
  Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.
  Michael T. Dellinger, Robert J. Hunter, Michael Bernas, Nicholas W. Gale, George D. Yancopoulos, Robert P. Erickson, Marlys H. Witte> ;Developmental Biology. 2008 Jul 15
• 36 citations
  Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia.
  Michael T. Dellinger, Robert J. Hunter, Michael Bernas, Marlys H. Witte, Robert P. Erickson> ;Developmental Dynamics. 2007 Aug 1
• Structural requirements of simple organic cations for recognition by multidrug-resistant cells.
  Dellinger M, Pressman BC, Calderon-Higginson C, Savaraj N, Tapiero H, Kolonias D, Lampidis TJ> ;Cancer Res.. 1992-11-15
• Join now to see all